CGFNS International Announces First Global Credential for Rehab Nurses

PHILADELPHIA, PA, June 28, 2024 – (ACN Newswire) – CGFNS International, a worldwide leader in international credentials evaluation to support health worker careers, has launched the first-ever global credential for registered nurses working in rehabilitation, habilitation or restorative care.

CGFNS Certified Global Nurse – Rehabilitation

The Certified Global Nurse – Rehabilitation (CGN-R) credential is intended to advance and improve services for the more than two billion people worldwide who need this care. It has been developed specifically for eligible registered nurses worldwide who wish to have their applied experience and competencies in rehab care recognized and verified by passing a certification examination.

The exam was created in collaboration with a global task force of more than 60 rehabilitation nursing experts from 17 countries who contributed their knowledge and guidance to develop a global competency framework for rehabilitation nursing and to create a test blueprint for a competency-based exam. The task force’s framework is aligned with the Rehabilitation Competency Framework established by the World Health Organization.

Accordingly, those who earn the CGN-R credential will be able to show their employers, prospective employers and others that they have been assessed against a global industry standard for rehabilitation care and that their expertise has been benchmarked against other nurses in rehab care worldwide.

Registration for the CGN-R exam will open in July, with testing dates to be scheduled for November. Registered (first-level) nurses with at least two years’ work experience in rehabilitation care are eligible to apply. Further details on eligibility requirements, exam topics and how to apply can be found in the exam handbook, now available at the CGFNS website.

“This will be the first global specialty certification offered anywhere for rehab nursing. It represents a huge shift for our global health workforce, for whom specialty credentials are often out of reach and require migration to the countries that offer them. The CGN-R certification will enable rehabilitation nurses everywhere to demonstrate a validated specialty skillset to their employers, carry the credential with them wherever they want to work in the world, and advance their career opportunities,” said Julia To Dutka, Chief of the CGFNS Global Health Workforce Development Institute, which is leading the initiative to develop this and other global credentials for the rehabilitation workforce.

“Provider certifications enable health systems and hospitals to confidently identify the most well-equipped workforce candidates to meet their burgeoning care needs. At a time when qualified interdisciplinary care teams are critically needed in rehabilitation care, the CGN-R establishes a global standard against which employers can set the bar for provider qualifications within their health systems,” said Terrence Carolan, Managing Director of Medical Rehabilitation and Aging Services of CARF International, an independent, nonprofit organization that accredits more than 66,000 rehabilitation and other health and human service providers on five continents and that has advised CGFNS in developing the CGN-R credential.

Nurses who sit for the initial CGN-R exam in November will receive a discount on exam fees.

CGFNS is also offering an early adopter program for hospitals, health systems or rehabilitation organizations that would like to invest in specialty certification for their rehab nurse workforce. The program includes opportunities to host the CGN-R exam onsite for their rehab nursing teams and earn an early adopter’s badge for organizational recognition.

Information on additional credentials for other health workers in a rehabilitative/habilitative/restorative environment – including physical and occupational therapists, speech-language pathologists and rehab technicians, among others – will be made available in the coming months.

More information on the program can be found at https://www.cgfns.org/services/certification/global-rehabilitation/

About CGFNS International, Inc.

Founded in 1977 and based in Philadelphia, CGFNS International is an immigration-neutral not-for-profit organization proudly serving as the world’s largest credentials evaluation organization for the nursing and allied health professions. CGFNS International is an NGO in Consultative Status with the United Nations Economic and Social Council (ECOSOC) and is a member of the Conference of NGOs in Consultative Relationship with the United Nations (CoNGO).

Contact Information
David St. John
dstjohn@cgfns.org

SOURCE: CGFNS International

HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)

ROCKVILLE, MD and SHENZHEN, CHINA, June 21, 2024 – (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the American Diabetes Association’s (ADA) 84th Scientific Sessions, taking place from June 21-24, 2024 in Orlando, Florida. The presentation is a post-hoc analysis of the Phase 2 clinical study of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, in patients with type 2 diabetes mellitus (T2DM) (NCT06411275).

Based on the successful Phase 2 study, two Phase 3 studies (NCT06350890, NCT06353347) are currently ongoing to further evaluate the efficacy and safety of HTD1801 (as monotherapy and as add-on to metformin) in patients with T2DM and inadequate control. “We look forward to the results of our pivotal T2DM program which we expect to announce in the first half of 2025,” said Dr. Leigh MacConell, Chief Development Officer of HighTide.

“Berberine Ursodeoxycholate (HTD1801) Improves Key Glycemic and Cardiometabolic Parameters Across the T2DM Disease Spectrum” (Abstract 847-P, Poster Presented June 23rd)

About the Abstract:

In a Phase 2, placebo-controlled, double-blind study in patients with T2DM, treatment with HTD1801 for 12 weeks resulted in significant dose-dependent improvements in key glycemic parameters. The objective of this post-hoc analysis was to evaluate the effectiveness of HTD1801 in patients with T2DM across the disease spectrum based on baseline HbA1c, with a particular emphasis on glycemic and lipid metabolism markers, along with indicators of liver injury. These data show that regardless of baseline disease severity, HTD1801 treatment resulted in significant improvements across these key parameters. The magnitude of improvement was greater in those with more severe disease. HTD1801 may offer a unique therapeutic approach for individuals with T2DM and other comorbidities (i.e. MASH and dyslipidemia), as managing these conditions effectively is crucial in controlling T2DM and reducing its associated complications.

About HighTide Therapeutics

HighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Disclaimer

The information contained herein is based solely on events or data available as of the date of this document. Unless required by law, we are under no obligation to update or publicly revise any forward-looking statements or events beyond those anticipated, even if new information, future events, or other circumstances arise after the date of the forward-looking statement. Please review this document carefully and be aware that our actual future performance or results may significantly deviate from expectations. All statements in this document are made as of the publication date and may change considering future developments.

For more information, please visit www.hightidetx.com

Contact: pr@hightidetx.com

DC Healthcare’s Approve All Resolutions in AGM

KUALA LUMPUR, June 12, 2024 – (ACN Newswire) – DC Healthcare Holdings Berhad (“DC Healthcare” or the “Group”), an aesthetic medical services provider specialising in the provision of non-invasive and minimally invasive procedures, is pleased to announce the successful completion of its Second Annual General Meeting (“AGM”) held virtually on June 11, 2024. The AGM was conducted through Remote Participation and Voting facilities, allowing shareholders to actively participate and cast their votes on key resolutions.

During the AGM, shareholders approved all the resolutions including the adoption of the Audited Financial Statements for the year ended December 31, 2023. Key resolutions passed also involved the re-election of directors, ratification of directors’ fees, and the re-appointment of Messrs. Moore Stephens Associates PLT as the Company’s auditors.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare expressed his gratitude to the shareholders, said, “We are incredibly thankful for the continued support and trust our shareholders place in us. This AGM not only reflects our commitment to transparency and robust corporate governance but also sets the path for our strategic initiatives aimed at enhancing service excellence and expanding our market presence. As we move forward, we remain dedicated to leveraging our strengths to drive sustainable growth and deliver value to all our stakeholders.”

Looking ahead, DC Healthcare is dedicated to strengthening its position in the medical aesthetics sector by implementing focused business strategies. These include expanding our clinics across Southern and Northern Malaysia, recruiting highly skilled and experienced staff, and continuously upgrading medical equipment with the latest technology to support growth and improve service quality. The Group remains optimistic about its future, bolstered by competitive advantages that are well-suited to drive sustainable growth in a dynamic market.

DC Healthcare Holdings Berhad https://dchealthcareholdings.com/

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)

ROCKVILLE, MD and SHENZHEN, CHINA, June 5, 2024 – (ACN Newswire) – HighTide Therapeutics, Inc. (HKEX: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. The presentations include post-hoc analyses of the Phase 2a clinical study of berberine ursodeoxcyholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, in patients with metabolic dysfunction-associated steatohepatitis (MASH) and comorbid type 2 diabetes mellitus (T2DM) (NCT03656744).

“These data provide additional insight on the potential benefits of HTD1801, a novel, multifunctional therapy being developed for the treatment of patients with MASH and T2DM. The ongoing multi-regional Phase 2b study (CENTRICITY, NCT05623189), now fully enrolled, evaluates the histologic benefit of HTD1801 in this same patient population. We look forward to the results of CENTRICITY which is on track to read out in the first half of 2025,” said Dr. Leigh MacConell, Chief Development Officer of HighTide.

“Efficacy of Berberine Ursodeoxycholate (HTD1801) Compared to Ongoing Use of GLP-1 Receptor Agonists in Patients with MASH and T2DM” (Abstract SAT-227, Poster Presented June 8)

About the Abstract: As GLP-1 Receptor Agonists (GLP-1RAs) are prominently used in patients with T2DM and gaining attention as a potential treatment for MASH, this post-hoc comparative efficacy analysis evaluated ongoing GLP-1RA use compared to newly initiated HTD1801 treatment. This analysis suggests that HTD1801 provides greater benefit across multiple cardiometabolic endpoints compared to ongoing GLP-1RA use. These findings are important as they suggest that patients with MASH and T2DM, on concomitant GLP-1RA treatment, could achieve additional benefit with HTD1801 in terms of further glucose and lipid lowering as well as weight loss.

“Berberine Ursodeoxycholate (HTD1801) Provides a Unique Therapeutic Approach for Patients with Metabolic Liver Disease and Severe Insulin Resistance” (Abstract SAT-225, Poster Presented June 8)

About the Abstract: Insulin resistance is a significant risk factor for T2DM, obesity and MASH. HTD1801 enhances the utilization of glucose and fats through activation of AMP-activated protein kinase (AMPK), thereby improving insulin sensitivity. As HTD1801 is under development as a treatment for patients with MASH and T2DM, the objective of this post-hoc analysis was to evaluate the effects of HTD1801 based on degree of insulin resistance. These data demonstrate that HTD1801 can alleviate the metabolic inhibitory effects caused by hyperinsulinemia, leading to even greater metabolic benefits in patients with MASH and more severe insulin resistance and therefore may offer a unique therapeutic approach for individuals with MASH and T2DM.

“Time Course of Onset, Incidence, and Prevalence of Gastrointestinal Adverse Events with HTD1801 (Berberine Ursodeoxycholate) in Patients with MASH and T2DM” (Abstract SAT-243, Poster Presented June 8)

About the Abstract: The most commonly occurring adverse events (AEs) in studies of HTD1801 across several indications have been mild to moderate gastrointestinal (GI) AEs, primarily diarrhea and nausea. The purpose of this post-hoc analysis was to characterize the time course and severity of GI AEs in patients with MASH and T2DM treated with HTD1801 for 18 weeks. Diarrhea and nausea, the most commonly occurring of GI AEs, followed a trend that was consistent with all reported GI AEs; they showed early onset (within the first 4 weeks), were mild or moderate in severity, and importantly, showed a decreasing incidence and prevalence over the course of treatment. These data demonstrate that with continued treatment with HTD1801, GI tolerability improves supporting its potential for long-term use for the treatment of chronic disease, such as MASH.

About HighTide Therapeutics

HighTide Therapeutics, Inc. (HKEX: 2511) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Disclaimer

For more information, please visit www.hightidetx.com.

Contact: pr@hightidetx.com

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Deliver 30% Savings, Halve Timelines and Cut Risk for Biotechs

WAKE FOREST, N.C. | ADELAIDE, AUS, June 4, 2024 – (ACN Newswire) – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, is sharing new data at BIO 2024 from Frost & Sullivan research showing biotechs save more than 30% in costs and halve start-up times with CROs that have in-house scientific and regulatory affairs.

Meet the team at BIO 2024 Booth #5601

DOWNLOAD THE REPORT HERE

According to the report key benefits for biotechs with CROs that have in-house scientific and regulatory affairs included:

Decrease trial startup timelines by up to 50% by supporting sponsors in preparing the study protocols, reviewing essential documents and prepping site for activation.
Reduced compliance risk and achieve zero errors by preparing necessary regulatory documents, compile submission dossiers and manage responses with regulatory authorities
Decreased cost to sponsors by up to 30% by enabling sponsors to leverage benefits of full-service CRO services and avoiding standalone contracts with independent regulatory affairs agency.

Avance Clinical’s Chief Scientific Officer Gabriel Kremmidiotis said some of the biotech services offered by the Avance Clinical in-house Scientific and Regulatory Affairs team included:

Regulatory Strategy Development: We devise regulatory strategies to navigate diverse regulatory landscapes, ensuring timely submissions and approvals.
Liaison with Regulatory Authorities: We serve as the primary liaison between our clients and regulatory authorities, maintaining open lines of communication and addressing inquiries promptly.
Surrogate Development: Acting as a surrogate development department, we assist start-up companies in demonstrating safety and preliminary clinical proof of concept of their assets.
Streamlined Marketing Application: Our medium-term aim is to offer a streamlined and flexible marketing application experience to our clients through our fully integrated functions within SRMA, harnessing our comprehensive global expertise.
Adherence to GCP Standards: We utilize quality systems that uphold adherence to Good Clinical Practice (GCP) standards, safeguarding the integrity and ethical conduct of clinical trials.

Avance Clinical recent news:

Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to later phase trials.

Avance Clinical CEO, Yvonne Lungershausen said “It’s clear there is a demand for a mid-sized, agile, and responsive CRO with an in-house regulatory affairs team, and a proven track record of swiftly advancing high-quality clinical programs”.

“Our Australian and New Zealand operations have been delivering successful early phase clinical trials for decades, while our European and North American operations as well as our new Asia operations makes us an ideal CRO partner for later phase biotechs that are seeking access to significant patient populations,” she said.

“Our global teams offer our biotech clients world-class quality data and seamless geographic expansions to accelerate their drug development programs and position for success.”

“Avance Clinical’s study data is accepted by all the main regulatory authorities including the EMA and FDA.”

“Biotechs are looking for a partner that can start fast with high-quality data that is readily accepted by the US FDA and other regulatory agencies. Backed by our in-house global regulatory affairs team, we can navigate biotechs through regulatory complexities with confidence including FDA, EMA, MFDS and TGA submissions,” she said.

“In addition, our GlobalReady Site Partnership Network of over 2,500 highly qualified sites across the globe ensures maximum efficiency and effectiveness for our biotech clients’ trials.”

Lungershausen said this is our GlobalReady program and we currently have more than 90 biotech clients leveraging this unique, streamlined multi-phase and multi-region process. “With a globalized strategy, we ensure efficiency every step of the way,” she said.

DOWNLOAD THE REPORT HERE

Find out more:

Learn about the GlobalReady model
For more information about the benefits of running your next study with Avance Clinical contact us
Request a Proposal here

Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson

About Avance Clinical

Avance Clinical is the largest premium full-service Australian and North American CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company’s clients are biotechs completing Phase I to Phase III of their drug development program that requires fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than 26 years.

Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right from pre-clinical through to Phase III clinical services leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.

www.avancecro.com

Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical

WAKE FOREST, N.C. | ADELAIDE, AUS, May 31, 2024 – (ACN Newswire) – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS, cardiometabolic, and rare diseases specialist CRO with extensive site relationships in the region.

Meet the Avance Clinical team at BIO 2024 – Book a meeting now.

Julius Clinical, established in 2008 and headquartered in Zeist, The Netherlands, specializes in CNS, cardiometabolic, and rare diseases. The non-exclusive MOU between Avance Clinical and Julius Clinical offers a streamlined global solution for biotech clients.

Avance Clinical CEO, Yvonne Lungershausen noted that Avance Clinical has expanded globally establishing operations now in Europe, Australia, New Zealand, Asia and North America.

She emphasized, “Avance Clinical is now a global CRO for biotechs. In addition to our existing operations, our specialist partner CROs work alongside our teams to ensure our biotech clients benefit from the most experienced scientific, regulatory, and clinical operations teams across various therapeutic areas and regions”.

“Julius Clinical are an ideal partner for Avance Clinical because they lead with scientific expertise and can support our biotech clients with specialist CNS, cardiometabolic and rare diseases clinical operations and site relationships in Europe,” Lungershausen said.

She added, “Julius Clinical clients can also leverage Avance Clinical operations in Asia, Australia, New Zealand, and North America for their expanded later phase trials”.

Julius Clinical has supported over 380 clinical trials, enrolling more than 220,000 participants in around 39 countries.

Lungershausen said that Avance Clinical teams across Europe, Australia, New Zealand, Asia, and North America provide world-class data and facilitate seamless geographic expansions to accelerate drug development programs, with study data accepted by regulatory authorities including the EMA and FDA.

Martijn Wallert, CEO of Julius Clinical, added, “We are excited to be partnering with Avance Clinical. Biotechs seek partners that can start quickly with high-quality data accepted by regulatory agencies like the MHRA, EMA, and US FDA. Together with Avance Clinical, we offer a nimble, flexible, and scientifically robust service, providing a tailored global solution”.

Avance Clinical is committed to accelerating drug development for biotech clients from early to later phase trials, allowing clients to remain with one CRO throughout their clinical development program. “This is our GlobalReady program, currently utilized by more than 90 biotech clients. Our globalized strategy ensures efficiency at every step,” Lungershausen concluded.

Find out more:

Learn about the GlobalReady model
For more information about the benefits of running your next study with Avance Clinical contact us
Request a Proposal here

Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson

About Avance Clinical

Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than 26 years.

Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical consulting and regulatory services with their experienced ClinicReady team right from pre-clinical through to Phase III clinical services leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.

www.avancecro.com

About Julius Clinical

Julius Clinical, founded in 2008 and based in Zeist, The Netherlands, is a scientifically focused CRO providing end-to-end clinical trial service to pharmaceutical and biotechnology customers, as well as governments and academia. Julius Clinical’s renowned scientific leaders are at the forefront of their fields, which combine with operational excellence and a global network of research sites to deliver tailor-made solution for customers and their clinical trials. With a focus on the therapeutic areas of CNS, cardio-metabolic, renal, and rare diseases, Julius Clinical has grown to approximately 200 employees and has supported over 380 clinical trials, enrolling more than 220,000 participants in around 39 countries.

www.juliusclinical.com

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

HEIDELBERG, Germany, May 28, 2024 – (ACN Newswire) – German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders. The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies.

This research project was launched in 2020 at the BioMed X Institute in Heidelberg and led by Dr. Ebru Ercan Herbst, now a professor at Reutlingen University, Germany. Her team has created both in vivo and in vitro platforms to study myelination of neurons and the development of oligodendrocytes – a subtype of glial cells – in the context of schizophrenia. Their novel in vitro platform for studying myelination was published last year in Cell Press – STAR Protocols (PMID: 36933222). Dr. Ercan Herbst’s team has also identified a relevant mouse model exhibiting the hypomyelination pathology associated with schizophrenia to be used for future research. In addition to the cell and mouse models, the BioMed X neuroscientists have analyzed the RNA expression of different human brain regions in post-mortem samples from schizophrenia patients and controls. Their soon-to-be-published findings reveal that there are differentially expressed genes and pathways in schizophrenia brains, particularly in oligodendrocytes, when compared to control brains, which could have significant implications for designing new therapies, not only for schizophrenia but also for other neurological disorders like major depressive disorder or bipolar disorder, which share a common hypomyelination pathology.

Dr. Christian Tidona, Managing Director & Founder of the BioMed X Institute: “This is already our second successfully completed project with Boehringer Ingelheim in the field of psychiatry. We are looking forward to continuing our successful collaboration with our ongoing research projects in brain sensor development in Heidelberg and in the field of wound healing and fibrosis at our new joint XSeed Labs on the U.S. campus of Boehringer Ingelheim in Ridgefield, CT.”

“Together with partners from across the global neuroscience community, we are constantly exploring new scientific avenues to address the huge unmet need of those living with mental health conditions,” Hugh Marston, Global Head CNS Discovery Research at Boehringer Ingelheim, stated. “The partnership with BioMed X and the fruitful collaboration with Dr. Ercan Herbst’s team has yielded exciting insights that will help us initiate projects to further progress our precision psychiatry approach to transform patients’ lives.”

About BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information

Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27

SOURCE: BioMed X Institute

New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim

RIDGEFIELD, CT, May 16, 2024 – (ACN Newswire) – XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team’s main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently.

The new research team is led by Dr. Lorenzo Talà, Group Leader at XSeed Labs. “Due to insufficient understanding of the mechanisms driving their pathology, therapies to treat fibrotic diseases are limited. The aim of our research group is to develop physiologically relevant in vitro and in silico fibrosis models. By combining both approaches, we will interrogate disease mechanisms, identify drug delivery pathways, and assess drug safety in order to facilitate drug development toward resolving fibrotic tissues.”

Christian Tidona, Founder and Managing Director of the BioMed X Institute: “We are pleased that we could successfully translate the innovation model we established in Heidelberg and New Haven to work inside a major pharma research and development campus. We have a long history of successful collaboration with Boehringer Ingelheim at our Heidelberg institute, and we are proud to extend this collaboration to their U.S. headquarters in Ridgefield, Connecticut.”

“We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases,” said Carine Boustany, PhD, U.S. Research Site Head and Global Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim. “In parallel, we will harness these innovative disease model systems to assess the safety of novel anti-fibrotic concepts, and identify better ways to deliver our molecules,” said Xiaorong He, PhD, U.S. Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim.

“We are excited to start our first XSeed Labs team at Boehringer Ingelheim in Ridgefield. It is the beginning of a unique innovation model that promotes scientific exchange between major players in biomedical research,” says Mark Johnston, CEO of BioMed X USA.

About BioMed X and XSeed Labs

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds — academia and industry — and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model – called XSeed Labs – entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.

Contact Information

Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27

Related Images

SOURCE: BioMed X Institute & XSeed Labs

View the original press release on newswire.com.

AsiaMedic partners with Sunway to establish new diagnostic imaging centre

The planned close to 6,000 sqft facility at Royal Square in Novena is expected to commence operations by November 2024 and will nearly double AsiaMedic’s diagnostic imaging capacity.
AsiaMedic’s continued capacity expansion follows three consecutive years of revenue growth which reached a record high for FY2023.

SINGAPORE, May 14, 2024 – (ACN Newswire) – SGX Catalist-listed AsiaMedic Limited (the “Company” and together with its subsidiaries, the “Group”) announced that the Company’s wholly-owned subsidiary, AMC Healthcare Pte. Ltd (“AMC”), has entered into a shareholders’ agreement with Sunway Equity Holdings Pte. Ltd. (“SEH”) to set up and operate a new medical diagnostics imaging centre in Novena, Singapore.

Mr Arifin Kwek, Chief Executive Officer of AsiaMedic Limited and Ms Sarena Cheah, Executive Director of Sunway Berhad [L-R]

AMC and SEH will establish AsiaMedic Sunway Pte. Ltd. to operate the new centre in Novena, which will provide a comprehensive range of general imaging as well as sub-specialised fields of radiology imaging such as computed tomography (CT) scans and magnetic resonance imaging (MRI) scans using the latest equipment.

Mr Arifin Kwek, Chief Executive Officer of AsiaMedic Limited, said, “The partnership with Sunway presents an opportunity for expansion of the Group’s diagnostic imaging business into Novena, which is a significant healthcare and medical services hub in Singapore. This will greatly complement the Group’s existing integrated medical centre at Orchard Road and enable us to serve more patients with greater convenience.”

The new diagnostic imaging centre will offer the same cutting-edge imaging services as the Group’s flagship centre at Orchard Road, which significantly expanded its capacity in September 2023 by being the first in Asia Pacific to operate the SIGNA™ Hero 3T MRI scanner. Once completed, the new centre in Novena will nearly double the Group’s diagnostic imaging capacity.

In FY2023, diagnostic imaging and radiology services revenue increased by 72% and contributed nearly 50% of Group revenue. Demand for the Group’s services remained strong across the entire spectrum of healthcare providers with an increase in referrals from clinics and hospitals.

Ms Sarena Cheah, Executive Director of Sunway Berhad, said, “We are confident in the long-term prospects of our partnership as AsiaMedic has a trusted track record and aptitude in providing tailored offerings to its patients. In addition, the new diagnostic imaging centre’s strategic location and close proximity to other healthcare providers will position us as the preferred choice for patients. This partnership will offer strategic benefits to Sunway and enhance our existing healthcare ecosystem.”

SEH is wholly-owned by Sunway City Sdn Bhd which in turn is wholly-owned by Sunway Berhad, one of Southeast Asia’s most prominent conglomerates and one of the leading private healthcare groups in Malaysia.

AsiaMedic continues to invest in the latest technology to enhance the patient experience and maintain its position as a preferred provider of diagnostic imaging radiology services. In March 2024, the Group became the first in Singapore to install the latest Revolution™ Apex Elite CT scanner. The Group will also continue to explore potential opportunities for further expansion and long-term growth.

This press release should be read in conjunction with the announcement uploaded on SGXNet.

For media and analysts’ queries, please contact:
Waterbrooks Consultants
Wayne Koo
T: (65) 9338 8166
E: wayne.koo@waterbrooks.com.sg

About AsiaMedic Limited

AsiaMedic Limited together with its subsidiaries (“AsiaMedic” or the “Group”) is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to prevent and detect early illnesses to achieve positive experiences and clinical outcomes for patients.

The Group is committed to helping clients through practical and personalised solutions delivered with the highest professional standards of service and expertise in a timely, safe and consistent manner. Conveniently located at Orchard Road, AsiaMedic is a preferred one-stop centre for:

Diagnostic imaging and radiology services
Medical wellness and health screening services
Primary healthcare services
Medical aesthetic services and products

For more information, please visit www.asiamedic.com.sg

Vinmec’s Innovations Spotlighted at Global CSR & ESG Summit 2024

HANOI, Vietnam, May 9, 2024 – (ACN Newswire) – The 16th Annual Global CSR & ESG Summit & Awards 2024 was held on April 25 in Hanoi, Vietnam. The event showcased tremarkable strides in corporate social responsibility (CSR) and environmental, social, and governance (ESG) initiatives, and featured some of the most outstanding achievements by enterprises and organizations in this regard.

Vietnam’s Vinmec Healthcare System received platinum awards for Best Community Program, Best Workplace Practices, Empowerment of Women, and Best Country Excellence in Vietnam in the US$1 billion and above market capitalization category.

Founded in 2012 to contribute to sustainable development in the Vietnamese healthcare sector by delivering high-quality medical services, Vinmec stands as a beacon of academic healthcare, dedicated to shaping the global healthcare narrative through innovative research, groundbreaking discoveries, and a steadfast commitment to clinical excellence and value-based care solutions.

In an interview with ACN Newswire, Vinmec CEO Le Thuy Anh discusses the company’s visionary objectives and operational aspirations, and how, amid an era marked by pressing healthcare challenges, the company’s resilience, foresight, and unwavering dedication are helping transcend geographical boundaries by creating a sustainable healthcare ecosystem.

ACN: Can you share with us the vision and mission of Vinmec, particularly its dedication to academic healthcare for people at local and global scales?

Le Thuy Anh: Vinmec’s vision revolves around addressing critical healthcare challenges nationally and globally, especially in light of the transition from communicable to non-communicable diseases and an aging population. Vinmec is pioneering as an agent of change based on a model of academic medicine with three pillars: excellence in clinical programs; innovative research; and medical education. Aligning with this vision, Vinmec’s mission is caring with compassion, professionalism, and wisdom based on the core values of C.A.R.E (Creativity, Accountability, Reliability, Excellence). Based on this, we aim to contribute significantly to sustainable healthcare development by delivering high-quality medical services, focusing on academic healthcare through innovative research and clinical excellence.

ACN: How does Vinmec approach innovation, research, and breakthroughs to achieve clinical excellence?

Le Thuy Anh: Our approach to innovation and research is integral to achieving clinical excellence. We invest significantly in research and technology transfer, operate research institutes like Vinmec Research Institute of Stem Cells and Gene Technology (VRISG) for stem cell therapies, and the Hi-tech Center for groundbreaking trials.

VRISG is a pioneering research institute specializing in stem cell therapies for a range of rare diseases and is also the first to utilize CAR-T cell therapy for leukemia treatment in Vietnam. Vinmec’s Hi-tech Center has achieved significant milestones, including conducting large-scale clinical trials for COVID-19 vaccines, successful international clinical trials on the efficacy of new cancer drugs, and becoming a reference laboratory for renowned medical partners like AstraZeneca.

Our emphasis on cutting-edgeinnovative applications like 3D printing and robotic surgery ensures clinical excellence and value-based solutions for our patients.

ACN: Creativity is highlighted as a core value of Vinmec. Can you provide examples of how the organization fosters continuous innovation to offer patients the best solutions?

Le Thuy Anh: Creativity drives our long-term development and breakthroughs, evident in our research findings turned into clinical trials like Car-T cell therapy for leukemia and stem cell transplantation in the treatment of autism and cerebral palsy, to name a few.

We empower our doctors with modern techniques and equipment through many training and clinical observership programs in the developed countries of medicine. We continuously innovate in workplace practices through initiatives like the Creativity Subcommittee, Kaizen, PDSA, and lean operations fostering a culture of excellence and implementing ideas that enhance quality and customer experience at all levels.

ACN: Accountability is crucial in healthcare. How does Vinmec ensure the highest level of accountability to patients and their families in terms of care ethics, skills, knowledge, and professional standards?

Le Thuy Anh: We ensure accountability through JCI accreditation, rigorous safety programs, and continuous training for our staff. Vinmec is the first and only healthcare system in Vietnam having two hospitals accredited by Joint Commission International (JCI) – the world’s most rigorous standards in hospital quality and patient safety.

Our focus on patient safety, through programs like Daily Safety Huddles where we hold a brief meeting in the morning between specialties, heads of departments, and other stakeholders to discuss clinical issues of patients; and the SpeakupSpeak up for every clinical staff to share and point out the patient’s risks reflects our commitment to the highest professional standards and ethics in delivering healthcare services.

Vinmec’s people play a key role in delivering the highest quality levels of healthcare, so we focus on continuous training and the well-being of the staff. As the first and only private academic healthcare model in Vietnam, excellence through persistent and personalized education is decisive for all Vinmecers, leading to delivering best practices.

ACN: Reliability is emphasized as a core value of Vinmec. How does the organization demonstrate its commitment to being the most reliable healthcare provider to the community?

Le Thuy Anh: Our commitment to reliability is evident through community initiatives, financial support for patients, and our response to healthcare crises like COVID-19.

Throughout 12the 12 years since its establishment, Vinmec has been entirely engaged in building a sustainable community.

Our business goals are always set in parallel with the benefits for the community at large. Thus, Vinmec is the only private healthcare system pursuing the model of a “not-for-profit” and value-based healthcare model in operation in Vietnam.

Vinmec’s contributions to the community are presented through community free health screening for over 15,000 people (in the past 5 years), financial support of VND300 billion annually for patients, medical education, and technology transfer for peer hospital and provincial hospitals.

Last but not least, Vinmec strongly responsed to Vingroup’s fight against COVID-19, making significant contributions in terms of human and material resources.

ACN: Excellence is a fundamental value for Vinmec. Could you discuss the organization’s approach to pursuing the highest service quality and implementing the best healthcare practices?

Le Thuy Anh: Pursuing excellence is at the core of our operations, seen through strategic partnerships, international accreditations, and Centers of Excellence for various disease groups.

Vinmec’s strategic partnerships with industry leaders like Cleveland Clinic and GE Healthcare have facilitated continuous improvement in service quality by leveraging advanced techniques and expertise. Over 12 years, Vinmec has received numerous international awards and accreditations, establishing Centers of Excellence (CoE) in critical areas like Cardiology, Orthopedics, Oncology, and Immunology, recognized globally for their cutting-edgeinnovative technology and specialist teams. Notably, the COE for Cardiology of Vinmec Times City International Hospital and Vinmec Central Park International Hospital were honored by the American College of Cardiology as the first centers of excellence in Asia.

Our focus on optimized treatment efficiency and outstanding service quality, along with continuous learning and improvement, ensures the best value-based solutions for our patients.

ACN: How does Vinmec ensure that compassion, professionalism, and wisdom are integrated into its care delivery model and reflected in the patient’s experience?

Le Thuy Anh: We take our responsibility extremely seriously and are committed to our mission of providing the utmost quality of care for our patients with professionalism, wisdom, and compassion. Our mission transcends the provision of healthcare services. It encompasses a commitment to nurturing a workplace where every member feels valued, respected, and motivated to excel.

At Vinmec, we believe in creating value not only for our patients but also for our people – the heart of our organization. This commitment is reflected profoundly in our workplace practices, where we strive to create an environment that not only fosters growth and recognition, but also integrates the core values of C.A.R.E (Creativity, Accountability, Reliability, Excellence) into every facet of our operations.

Our approach to workplace practices is holistic, focusing on the Total Rewards policies that motivate, develop, and nurture our employees. Holistic care extends through various stages of an employee’s journey, including recruitment, integration, promotion, training, and development. Meanwhile, Vinmec’s Comprehensive Care Program, “Vinmec Health & Wellbeing,” offers a holistic approach to employee wellness, encompassing mental and physical health, career development, and family and social connections. This initiative underscores Vinmec’s commitment to fostering a nurturing and supportive environment for all our staff, ensuring a well-rounded support system.

Our CARE culture forms the foundation of the Vinmec management framework. At Vinmec, we focus on value-based leadership, where our leaders exemplify the CARE principles in their daily actions. Vinmec has established a Cultural Framework with activities promoting the distinctive CARE culture. These activities are implemented deeply within the framework, following a planned timeline and themes for each quarter. The cultural activities have seen widespread and enthusiastic participation from members.

As a result, Vinmec is the first and only healthcare system in Vietnam that received the “Best Place to Work” award in 2023.

ACN: Looking ahead, what are the future plans and goals for Vinmec in terms of furthering its mission of academic healthcare and delivering excellence in patient care?

Le Thuy Anh: Our future plans include expanding our hospital network, treating rare diseases, promoting preventive medicine, and adopting advanced healthcare models. We aim to remain a factor of change and sustainability in Vietnamese medicine, delivering academic healthcare excellence and achieving international standards of care.

Vinmec has steadfastly pursued its vision of becoming Vietnam’s first academic private healthcare system, emphasizing creativity and innovation to address complex medical challenges and promote preventive medicine, patient engagement, and the adoption of P4 medicine (Predictive, Preventive, Personalized, Participatory).

The upcoming opening of two new Vinmec hospitals will expand its network to nine international hospitals nationwide, showcasing its ongoing commitment to excellence and attainment of world-class quality certificates.

About Vinmec

Vinmec is dedicated to academic healthcare for people at local and global scales through innovation research and breakthroughs that lead to clinical excellence and value-based care solutions. For more information visit, https://en.vinmec.com.

Media contact:
Tram Nguyen – Corporate Branding Specialist
v.tramnn17@vinmec.com